Open trial of recombinant Der f 2 pullulan-conjugated immunotherapy in cats
© 2023 ESVD and ACVD..
BACKGROUND: Allermmune HDM (Zenoaq) is a recombinant Dermatophagoides farinae 2 (Der f 2) pullulan-based immunotherapy vaccine whose efficacy on house dust mite allergic dogs has been demonstrated. There is no published information on its use in cats.
OBJECTIVES: The objective of the study was to evaluate the safety and short-term effects of Allermmune HDM in Dermatophagoides farinae (Df)-sensitised cats.
MATERIALS AND METHODS: Eleven cats diagnosed with atopic skin syndrome received Allermmune weekly for six weeks then monthly for three months (total duration 18 weeks). On Weeks 0, 6 and 18 clinical lesions were assessed by the Feline Dermatitis Extent and Severity Index (FEDESI); owners assessed pruritus with a 10-cm Visual Analog Scale (pVAS). Concurrent medication use was recorded. The allergen-specific immunoglobulin (Ig)E were measured before study inclusion with a commercial serological assay.
RESULTS: There were no evident adverse effects. FEDESI and pVAS improved significantly after six weeks (p = 0.001 and p = 0.01, respectively). The pretreatment Df-specific IgE levels were significantly higher in the cats with improved clinical scores than in the cats with no clinical score change (p = 0.009).
CONCLUSIONS AND CLINICAL RELEVANCE: Allermmune HDM may be safe in cats and has the potential to alleviate signs of atopic skin syndrome. Allergen-specific IgE levels may represent an efficacy marker. Controlled studies of longer duration and larger sample size are worth pursuing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Veterinary dermatology - 35(2024), 2 vom: 29. März, Seite 175-183 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martini, Franco [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/vde.13217 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365641154 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365641154 | ||
| 003 | DE-627 | ||
| 005 | 20240313233909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/vde.13217 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM365641154 | ||
| 035 | |a (NLM)38073305 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martini, Franco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Open trial of recombinant Der f 2 pullulan-conjugated immunotherapy in cats |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 ESVD and ACVD. | ||
| 520 | |a BACKGROUND: Allermmune HDM (Zenoaq) is a recombinant Dermatophagoides farinae 2 (Der f 2) pullulan-based immunotherapy vaccine whose efficacy on house dust mite allergic dogs has been demonstrated. There is no published information on its use in cats | ||
| 520 | |a OBJECTIVES: The objective of the study was to evaluate the safety and short-term effects of Allermmune HDM in Dermatophagoides farinae (Df)-sensitised cats | ||
| 520 | |a MATERIALS AND METHODS: Eleven cats diagnosed with atopic skin syndrome received Allermmune weekly for six weeks then monthly for three months (total duration 18 weeks). On Weeks 0, 6 and 18 clinical lesions were assessed by the Feline Dermatitis Extent and Severity Index (FEDESI); owners assessed pruritus with a 10-cm Visual Analog Scale (pVAS). Concurrent medication use was recorded. The allergen-specific immunoglobulin (Ig)E were measured before study inclusion with a commercial serological assay | ||
| 520 | |a RESULTS: There were no evident adverse effects. FEDESI and pVAS improved significantly after six weeks (p = 0.001 and p = 0.01, respectively). The pretreatment Df-specific IgE levels were significantly higher in the cats with improved clinical scores than in the cats with no clinical score change (p = 0.009) | ||
| 520 | |a CONCLUSIONS AND CLINICAL RELEVANCE: Allermmune HDM may be safe in cats and has the potential to alleviate signs of atopic skin syndrome. Allergen-specific IgE levels may represent an efficacy marker. Controlled studies of longer duration and larger sample size are worth pursuing | ||
| 650 | 4 | |a Clinical Trial, Veterinary | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IgE | |
| 650 | 4 | |a allergy | |
| 650 | 4 | |a atopic dermatitis | |
| 650 | 4 | |a cats | |
| 650 | 4 | |a der f 2 | |
| 650 | 4 | |a immunotherapy | |
| 650 | 7 | |a Allergens |2 NLM | |
| 650 | 7 | |a Antigens, Dermatophagoides |2 NLM | |
| 650 | 7 | |a Arthropod Proteins |2 NLM | |
| 650 | 7 | |a Dermatophagoides farinae antigen f 2 |2 NLM | |
| 650 | 7 | |a Glucans |2 NLM | |
| 650 | 7 | |a Immunoglobulin E |2 NLM | |
| 650 | 7 | |a 37341-29-0 |2 NLM | |
| 650 | 7 | |a pullulan |2 NLM | |
| 650 | 7 | |a 8ZQ0AYU1TT |2 NLM | |
| 700 | 1 | |a Rostaher, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Favrot, Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Nina M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Veterinary dermatology |d 1990 |g 35(2024), 2 vom: 29. März, Seite 175-183 |w (DE-627)NLM093697333 |x 1365-3164 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2024 |g number:2 |g day:29 |g month:03 |g pages:175-183 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/vde.13217 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2024 |e 2 |b 29 |c 03 |h 175-183 | ||